Drug class
Hepatitis D virus (HDV) entry inhibitor; myristoylated pre-S1 lipopeptide
Mechanism of action
Binds the sodium taurocholate cotransporting polypeptide (NTCP) receptor on hepatocytes, blocking entry of hepatitis B and D viruses into liver cells. It prevents new infection of hepatocytes but does not directly eliminate intracellular viral genomes.
General use cases
- Treatment of chronic hepatitis D virus (HDV) infection in adults with compensated liver disease, with or without concomitant HBV infection, under the EU-authorised Hepcludex indication; use in combination with HBV management as directed by specialist product information
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
